The recruitment telephone number Shijiazhuang Shi Mu Pharmaceutical Co., Ltd. was 17736936684, and the contact person was Ms. Zhang. Read more exciting novels for free
Cinda Biomedicals 'listed drugs include biosimilar drugs Adalimumab, Rituxan, and Bevacizumab, innovative drugs Xindilitumab (PD - 1), tolesidumab (PC SK9), and imported fluzarexed tablets (Kras G12C). In addition, there were 22 new drugs in the clinical stage, focusing on diseases such as cancer, autoimmunity, and metabolism diseases, covering monoclonals, bisected antibodes, CAR-T, and small molecular drugs. Five of them were in the critical phase II/III clinical stage, and NDA applications were about to be submitted for IBI376 (PI3K 6) and IBI326 (BCAR-T). There were also three heavyweight biological drugs that were about to be launched, namely, the PD - 1 monoclonab Sindilitumab, the Adalimumab-like drug (IBI303), and the bevacizumab-like drug (IBI305). <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Guofeng Pharmaceutical Co., Ltd. had recently recruited 44 positions in 29 regions (including Shandong, Beijing, Dalian, etc.). They were recruiting 2 masters, with the most categories of medical and health care/beauty care, accounting for 34%, college degree, accounting for 57%, and work experience of 1 - 3 years. In addition, there were also related positions such as Chinese medicine prescriptions. They required 1 - 3 years of work experience, a technical secondary school or technical secondary school degree, and the work address was Guofeng, North Gate, No. 101, Yan 'an Third Road. The responsibilities included being responsible for Chinese medicine prescriptions, storage, maintenance, display, etc. The novel,"The Morality of the Past", is equally exciting. Everyone is welcome to click and read it!
At present, it was only retrieved that on December 7,2020, Beidahuang Pharmaceutical Group held an open competition meeting for management positions to publicly select the position of the head of the enterprise management department. After screening, three people entered the competition, but no more recruitment information about Beidahuang Pharmaceutical Co., Ltd. was found. I'm sorry, but I don't know how to answer based on the information I found. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Hebei Renxin Pharmaceutical Co., Ltd. was a modern Chinese medicine production enterprise located in the Traditional Chinese Medicine Industrial Park of Anguo City, Hebei Province. The company was established on April 23, 2014 with a total investment of 56 million yuan and an area of 16 acres. Its business scope included the processing of Chinese herbal pieces, the wholesale of Chinese herbal medicines, the acquisition of agricultural and sideline products, the wholesale and retail of pre-packaged food, import and export trade, etc. The company currently has a general decoction piece production room and a direct oral decoction piece production workshop, and has passed the national GMP-certification. In addition, the company also invested in inspection equipment and production equipment to ensure product quality and production standards. The legal representative of Hebei Renxin Pharmaceutical Co., Ltd. was Xie Weisong.
The salary range of Xiansheng Pharmaceuticals was 6K-50K, of which the salary of 6K-8K accounted for the most, reaching 73.3%. The salary for a bachelor's degree was about 7.6K, and the salary for a master's degree was about 27.3K. The salary of a protein fermentation and purification technician was 5,000 - 7,000 yuan. The salary of a pharmaceutical sales ADC representative was 4000 - 9000 yuan per month, and the probation salary was 3000 yuan per month. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Dikang Pharmaceutical was recruiting 49 positions in 32 regions (Chengdu, Guangzhou, and Chongqing). There were intern recruitment positions, such as human resources interns, with a salary of 100 - 200 yuan per day. The work location was in High-tech Zone, and there was no requirement for academic qualifications. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Dikang Pharmaceuticals had 49 recruitment positions in 32 regions (such as Chengdu, Guangzhou, and Chongqing), including one intern, such as a human resources intern, with a salary of 100 - 200 yuan per day. The work location was in High-tech Zone. There was no limit to academic qualifications. The recruitment information was released 26 days ago. In addition, they were also looking for a marketing director position with an annual salary of 50k-65k. The requirements were more than 10 years of experience and a bachelor's degree. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Guizhou Magic Pharmaceutical Co., Ltd. mainly produces strong loquat dew, loquat cough granules, children's throat flat granules, children's detoxification syrup and other anti-flu drugs. It is also engaged in the production and sales of "Magic" brand cough and cold series products, Magic Doll children's series products, cardiovascular and other series of drugs. The categories of drugs include respiratory system drugs, cardiovascular and cardiovascular drugs, anti-tumor drugs, digestive system drugs, etc. Its main products include the injection of caprylylane, the injection of caprylane, the capsule of loquat cough, the capsule of Jinwu Gutong, the capsule of coral, the capsule of Jing Wu, the capsule of Tianma, the pill of Yin Dan Xin Tai, etc. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
It was difficult to fully evaluate the strength of Guangxi Kangdi Pharmaceutical Co., Ltd. based on the available information. In terms of business scope, there were permitted projects such as pharmaceutical wholesale, as well as general projects such as the acquisition of Chinese herbal medicine and housing rental, which showed that the business was diverse. The company had a registered capital of 3 million yuan and was in the state of opening in 2022. The legal representative was Qiu Yongchuan. However, due to the lack of information such as market share, research and development capabilities, and industry reputation, it was impossible to determine the strength of the company. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
You might want to know more about the company. It was a new drug research and development company established on September 17,2019. It was located in Room 203, 204, 205, 206 and 207, Building 6, Gaonong Biological Park Comprehensive Service Area (II), Zone B, No. 888 Gaoxin Avenue, East Lake New Technology Development Zone, Hubei Province. The company's scale was between 50 - 99 people. It was a start-up company, belonging to the pharmaceutical/bioengineering industry. It was a small and medium-sized technological enterprise and a provincial high-tech enterprise. Its core team members came from well-known pharmaceutical companies at home and abroad and had rich experience in the development of new drugs. The company focused on the research and development of a class of small molecular new drugs in the field of cancer and immune diseases. It adopted the asset-light model of "Vic"(ie, venture capital + intellectual property + Crow). The company had established close cooperative relationships with domestic universities such as WuMing AppTec, HuaZhong University of Science and Technology, and East China University of Science and Technology. In terms of biological testing, the company had entrusted WuMing AppTec, Wisdom Chemistry, Medici Biology, and other well-known domestic Crow companies to ensure the rapid and high-quality advancement of the project. At present, they have developed a number of target lead compounds, which performed well in in both in-and in-body experiments, and have reached a cooperative development agreement with well-known listed pharmaceutical companies. On September 1, 2024, the company obtained a patent called "Tricyclical Compound and its Pharmaceutical compositions and applications"(Grant Announcement No. CC114685520B, application date: December 2021). This compound and its pharmaceutical composition have good inhibition activity of the plk1, and can be used as a plk1 inhibition agent to prepare drugs for the treatment and/or prevention of diseases (such as cancer) that are overexpressed by plk1. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>